GSK plc (NYSE:GSK) Shares Sold by JTC Employer Solutions Trustee Ltd

JTC Employer Solutions Trustee Ltd lowered its position in GSK plc (NYSE:GSK) by 1.0% during the fourth quarter, Holdings Channel reports. The firm owned 20,278,564 shares of the pharmaceutical company’s stock after selling 202,398 shares during the period. GSK comprises 48.3% of JTC Employer Solutions Trustee Ltd’s portfolio, making the stock its largest holding. JTC Employer Solutions Trustee Ltd’s holdings in GSK were worth $682,272,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of the company. Thomasville National Bank grew its holdings in GSK by 3.4% in the fourth quarter. Thomasville National Bank now owns 491,441 shares of the pharmaceutical company’s stock worth $16,621,000 after purchasing an additional 16,057 shares during the period. Brookstone Capital Management grew its stake in GSK by 19.8% in the fourth quarter. Brookstone Capital Management now owns 31,701 shares of the pharmaceutical company’s stock valued at $1,072,000 after acquiring an additional 5,244 shares during the period. Fiduciary Alliance LLC bought a new stake in shares of GSK during the fourth quarter valued at approximately $390,000. Green Alpha Advisors LLC raised its position in shares of GSK by 17.7% during the fourth quarter. Green Alpha Advisors LLC now owns 27,316 shares of the pharmaceutical company’s stock worth $924,000 after purchasing an additional 4,107 shares during the period. Finally, ST Germain D J Co. Inc. grew its position in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the period. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, Guggenheim lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

GSK traded down $0.45 during trading on Monday, reaching $32.64. 2,359,896 shares of the company were exchanged, compared to its average volume of 2,857,900. The company’s 50-day moving average is $34.38 and its two-hundred day moving average is $38.17. GSK plc has a 12-month low of $32.55 and a 12-month high of $45.92. The company has a market cap of $67.65 billion, a price-to-earnings ratio of 21.19, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.81%. The ex-dividend date was Friday, November 15th. GSK’s dividend payout ratio is presently 95.45%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.